Each month, The American Journal of Managed Care hosts a Twitter chat (#AJMCchat) with a different expert. This month’s chat covered care pathways and featured Robert W. Dubois, MD, from the National Pharmaceutical Council.
Each month, The American Journal of Managed Care hosts a Twitter chat (#AJMCchat) with a different expert. This month’s chat covered care pathways and featured Robert W. Dubois, MD, from the National Pharmaceutical Council (NPC) with participation from other individuals on Twitter.
Let's jump into it! Q1. What are clinical pathways & how do they differ from guidelines? #AJMCchat
— AJMC (@AJMC_Journal) January 28, 2016
Q1 #CarePathways = a method for managing #patient care based on clinical practice guidelines #AJMCchat 3/3
— NPC (@npcnow) January 28, 2016
Care pathways, or clinical pathways, are generally defined as a method of managing patient care. When there is the potential for cost savings, high disease prevalence, great diversity in treatment patterns, or multiple branded therapies, care pathways often come into play. Ultimately, care pathways are intended to improve the quality, variation, and efficiency of care, and allow physicians increased flexibility in tailoring care to suit a patient’s needs.
As stakeholders continue to push for quality and value in their healthcare, they are looking more and more to care pathways as a means of achieving this.
Q3 Goals of #CarePathways: improve quality, reduce variation & increase efficiency of care #AJMCchat
— NPC (@npcnow) January 28, 2016
How much further care pathways are expected to evolve is subject to debate. Already care pathways have expanded from the field of cancer, the original clinical area to use care pathways, to conditions like diabetes and hypertension. Other influences may include financial incentives for healthcare personnel (HCPs) or an increase precision medicine. (Although some opinions say that precision medicine will limit care pathways rather than be incorporated by them.)
Currently, care pathways are typically handled as bundled payments or episode-based payments. The benefit of this is that the focus shifts to the outcome rather than the process; these types of payments may also make budgeting easier.
Q5. Why do bundled payments and episode-based payments work well with care pathways? #AJMCchat
— AJMC (@AJMC_Journal) January 28, 2016
Q5: Fixed dollars/ budget Not all you can eat buffet style! #AJMCchat https://t.co/QrMlKwQnK6
— Kevin J. Fowler (@gratefull080504) January 28, 2016
Primarily, vendors, payers, and major oncology network providers develop pathways. Care pathways are regulated by a variety of sponsoring organizations including the National Comprehensive Cancer Network, which monitors pathways, and the American Social of Clinical Oncology (ASCO), which monitors the guidelines for care pathways.
There have been, however, some concerns raised about the design and efficacy of care pathways. Some critics argue that there is not enough involvement in the development of care pathways, lacking either provider input or healthcare provider buy-in—both populations are key to care pathway implementation. In spite of organization sponsorship, there are no formal standards for the development, implementation, and evaluation of care pathways, and little to no studies on the impact of these care pathways, including quality control, resource use, costs, and patient outcomes.
Especially prevalent is a concern about transparency with patients. Participants in the chat, emphasized the need for patient engagement, to include patient voices in the design phase as they will be the primary recipients of this care. Effectiveness can only be achieved with collaboration, dialogue, and consistency.
Q4 Transparency is key. Patients need to know they are being managed by a #carepathway #AJMCchat
— NPC (@npcnow) January 28, 2016
NPC stressed the importance of patient dialogue, citing their own study and that of ASCO as evidence. Both studies examined the challenges of care pathways, offered recommendations for their improvement, and sought more research on the matter.
In order to measure the success of care pathways, NPC recommended that pathway compliance, quality metrics, hospitalizations, and healthcare provider satisfaction could be examined.
Q8 We also agree with @ASCO on further research needed on #CarePathways impact #AJMCchat
— NPC (@npcnow) January 28, 2016
NPC strives to monitor the development and implementation of care pathways in order to improve care and reduce costs.
On the next page, you will find the full chat.
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More